Meropenem — Membership Pricing

Other medications in Infections

• Minocycline
• Moxifloxacin
• Ofloxacin
• Oritavancin
• Oseltamivir
• Penicillin VK
• Polymyxin B
• Pyrazinamide

About Meropenem

Meropenem is a potent, broad-spectrum antibiotic essential for treating a range of severe bacterial infections. As a critical medication, its cost can be a concern. TheDrugClub membership program is designed to help you navigate these expenses, offering potential savings and access benefits on vital prescriptions like meropenem.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Meropenem is approved for (FDA label)

Meropenem for Injection is a penem antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). ( 1.1 ) • Complicated intra-abdominal infections (adult and pediatric patients). ( 1.2 ) • Bacterial meningitis (pediatric patients 3 months of age and older only). ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Complicated Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of Age and Older Only) Meropenem for injection, USP is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci , Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Complicated Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Bacteroides fragilis , B. thetaiotaomicron , and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for injection, USP is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae , Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae . Meropenem for injection, USP has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP and other antibacterial drugs, Meropenem for injection, USP should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Source: Read the full FDA label on DailyMed. Label effective date: August 26, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Meropenem (FDA label)

Single dose clear glass vials of Meropenem for Injection, USP containing 500 mg or 1 gram (as the trihydrate blended with anhydrous sodium carbonate for re-constitution) of sterile meropenem powder. 500 mg meropenem for Injection Vial ( 3 ) 1 gram meropenem for Injection Vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 8a2a545e-b336-416a-be73-9e0a7ccf6177. SPL document ID: c7a35300-aec1-427b-a7d1-3856ee841c45. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Meropenem (FDA label)

The following are discussed in greater detail in other sections of labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.2 )] Rhabdomyolysis [see Warnings and Precautions ( 5.3 )] Seizure Potential [see Warnings and Precautions ( 5.4 )] Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid [see Warnings and Precautions ( 5.5) ] Clostridioides difficile – associated Diarrhea [see Warnings and Precautions ( 5.6 )] Development of Drug-Resistant Bacteria [see Warnings and Precautions ( 5.7 )] Overgrowth of Nonsusceptible Organisms [see Warnings and Precautions ( 5.8 )] Thrombocytopenia [see Warnings and Precautions ( 5.9 )] Potential for Neuromotor Impairment [see Warnings and Precautions ( 5.10 )] Most common adverse reactions (2% or less) are: headache, nausea, constipation, diarrhea, anemia, vomiting, and rash ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Adverse Reactions from Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 8a2a545e-b336-416a-be73-9e0a7ccf6177. SPL document ID: c7a35300-aec1-427b-a7d1-3856ee841c45. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Meropenem (FDA label)

Meropenem for injection is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta (β)-lactams. Known hypersensitivity to product components or anaphylactic reactions to β-lactams. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 8a2a545e-b336-416a-be73-9e0a7ccf6177. SPL document ID: c7a35300-aec1-427b-a7d1-3856ee841c45. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Meropenem (FDA label)

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams. ( 5.1 ) Severe cutaneous adverse reactions have been reported in patients receiving meropenem for injection. ( 5.2 ) Rhabdomyolysis: If signs or symptoms of rhabdomyolysis are observed, discontinue meropenem for injection and initiate appropriate therapy. ( 5.3 ) Seizures and other adverse CNS experiences have been reported during treatment. ( 5.4 ) Co-administration of meropenem for injection with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures. ( 5.5 , 7.2 ) Clostridioides difficile- associated diarrhea (ranging from mild diarrhea to fatal colitis) has been reported. Evaluate if diarrhea occurs. ( 5.6 ) In patients with renal dysfunction, thrombocytopenia has been observed. ( 5.9 ) 5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams.

Source: FDA prescribing information (DailyMed). Set ID: 8a2a545e-b336-416a-be73-9e0a7ccf6177. SPL document ID: c7a35300-aec1-427b-a7d1-3856ee841c45. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Meropenem (FDA label)

Co-administration of Meropenem for injection with probenecid inhibits renal excretion of meropenem and is therefore not recommended ( 7.1 ) The concomitant use of Meropenem for injection and valproic acid or divalproex sodium is generally not recommended. Antibacterial drugs other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. ( 5.4 , 7.2 ) 7.1 Probenecid Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Co-administration of probenecid with meropenem is not recommended. 7.2 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.

Source: FDA prescribing information (DailyMed). Set ID: 8a2a545e-b336-416a-be73-9e0a7ccf6177. SPL document ID: c7a35300-aec1-427b-a7d1-3856ee841c45. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.